PMA supplement
P200019 S003: VENTANA MMR RxDx Panel (Endometrial Cancer with dMMR status)
FDA PMA supplement · 135 Review Track For 30-Day Notice · Ventana Medical Systems
Key facts
| Original PMA | P200019 |
|---|---|
| Supplement number | S003 |
| Supplement type | 135 Review Track For 30-Day Notice |
| Reason for the supplement | Process Change - Manufacturer/Sterilizer/Packager/Supplier |
| Trade name | VENTANA MMR RxDx Panel (Endometrial Cancer with dMMR status) |
| Generic name | Immunohistochemistry test, DNA mismatch repair (MMR) Protein assay |
| Applicant | Ventana Medical Systems |
| Product code | QNH |
| Received date | Jan 28, 2022 |
| Decision date | Jun 10, 2022 |
At a glance
- No Expedited review granted
- No Approval order on file
- No Summary of safety and effectiveness on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMA supplements
A PMA supplement asks FDA to approve a change to a device that already holds a premarket approval: a new indication, a design or labeling change, a manufacturing site or process change.
Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date: